Science & Technology: Receptor-Associated Protein (RAP) and Mesoderm Development Protein (Mesd) Drug-targeting Platforms

Raptor is developing drug-targeting platforms based on the proprietary use of the human protein called receptor-associated protein (RAP) and the mesoderm development protein (Mesd). Raptor believes that these proteins may have therapeutic applications in cancer, infectious diseases and neurodegenerative diseases, among others.

These applications are based on the assumption that our targeting molecules can be engineered to bind to a selective subset of receptors with restricted tissue distribution under particular conditions of administration. Raptor believes these selective tissue distributions can be used to deliver drugs to the liver or to other tissues, such as the brain.

In addition to selectively transporting drugs to specific tissues, selective receptor binding constitutes a means by which receptor function might be specifically controlled, either through modulating its binding capacity or its prevalence on the cell surface. Mesd is being engineered for this latter application.

Raptor's Receptor-Associated Protein (RAP) Drug-targeting Pipeline

• HepTide™ for the potential treatment of primary liver cancer and other liver diseases
• NeuroTrans™ for the potential delivery of therapeutics across the blood-brain barrier

Raptor's Mesoderm Development Protein (Mesd) Product Candidate

• WntTide™ for the potential treatment of breast cancer

Data Supports Potential Efficacy of WntTide™ in Treatment of Triple-Negative Breast Cancer

Raptor is currently evaluating WntTide™ in a preclinical breast cancer model to inhibit the Wnt-signaling pathway designed to block cancers dependent upon signaling through LRP6.

Claims to Cover Therapeutic Delivery Across Blood-Brain Barrier

Raptor's patent application for NeuroTrans™ may generally cover the use of its proprietary RAP peptides for delivery into the central nervous system. The claims broadly encompass all neurological disorders, including Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, Multiple Sclerosis, and Amytrophic Lateral Sclerosis.